[1. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg. 2013; 21:118-26.10.5435/JAAOS-21-02-118]Search in Google Scholar
[2. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P et al. Distinct h3f3a and h3f3b driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45:1479-82.10.1038/ng.2814]Open DOISearch in Google Scholar
[3. Zhen W, Yaotian H, Songjian L, Ge L, Qingliang W. Giantcell tumor of bone. The long-term results of treatment by curettage and bone graft. J Bone Joint Surg (Br). 2004; 86:212-6.10.1302/0301-620X.86B2.14362]Open DOISearch in Google Scholar
[4. Branstetter DG, Nelson SD, Manivel JC et al. Denosumab induces tumour reduction and bone formation in patients with giant cell tumour of the bone. Clin Cancer Res. 2012; 18:4415-4424.10.1158/1078-0432.CCR-12-057822711702]Open DOISearch in Google Scholar
[5. Ueda T, Morioka H, Nishida Y et al. Objective tumour response to denosumab in patients with giant cell tumour of the bone. Ann Surg Oncol. 2015; 22:2860-2868.10.1245/s10434-015-4634-9]Search in Google Scholar
[6. Aghaloo TL, Felsenfeld AL, Tetradis S et al. Osteonecrosis of the jaw in a patient on denosumab. J of the American Association of Oral Maxilofacial Surgeons. May 2011; 68(5):959-963.10.1016/j.joms.2009.10.010]Search in Google Scholar
[7. Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016, Mar; 27(3):367-75.10.1111/clr.12556]Search in Google Scholar
[8. Thomas D, HenshawR, Skubitz L et al. Denosumab in patients with giant-cell tumour of the bone: an open label, phase 2 study. Lancet Oncol. 2010; 11:275-280.2014973610.1016/S1470-2045(10)70010-3]Search in Google Scholar
[9. Rutkowski P, Ferrari S, Grimer RJ et al. Surgical downstaging in an open label phase II trial of denosumab in patients with giant cell tumour of the bone. Ann Surg Oncol. 2015; 22:2860-2868.10.1245/s10434-015-4634-9]Search in Google Scholar
[10. Chawla S, Henshaw R, Seeger L et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of the bone: interrim analysis of an open label, parallel- group, phase 2 study. Lancet Oncol. 2013; 14:901-908.2386721110.1016/S1470-2045(13)70277-8]Search in Google Scholar
[11. Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR et al. Sclerostin and dkk1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res. 2012; 27:2259-63.10.1002/jbmr.168122692843]Search in Google Scholar
[12. Fumihiro I, Nakamura Y. Effects of Denosumab Treatment during Early Pregnancy - A Case Report. Journal of Nutritional Disorders & Therapy. 2015; 06. 10.4172/2161-0509.1000189.10.4172/2161-0509.1000189]Search in Google Scholar
[13. Chaudhary P, Khadim H, Gajra A, Damron T, Shah C. Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor. Onkologie. 2011; 34:702-4.10.1159/00033454922156450]Open DOISearch in Google Scholar